Cellebrite DI Ltd. (CLBT) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Cellebrite DI’s revenue went from $172M in fiscal 2019 to $476M in fiscal 2025, growth of about 18.5% a year.
Net income in fiscal 2025 was $78M, a net margin of 16.5%; the best year in this period was 2022 with $121M.
Over the twelve months to September 30, 2026, revenue was $537M and net income $65M.
Free cash flow was $160M in fiscal 2025 and positive in 7 of the 7 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $537M | $476M | $401M | $325M | $271M | $246M | $195M | $172M |
| Gross profit | — | $401M | $339M | $272M | $220M | $204M | $157M | $136M |
| Operating income | — | $66M | $57M | $33M | $1M | $14M | $9M | -$2M |
| Net income | $65M | $78M | -$283M | -$81M | $121M | $71M | $6M | -$2M |
| EPS (diluted) | $0.26 | $0.31 | $-1.13 | $-0.32 | $0.48 | $0.28 | $0.02 | $-0.01 |
| R&D | — | $114M | $98M | $84M | $81M | $66M | $54M | $47M |
| Revenue growth | — | +18.6% | +23.4% | +20.1% | +9.9% | +26.3% | +13.4% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $181M | $174M | $132M | $102M | $21M | $36M | $67M | $16M |
| Capital spending | -$39M | -$13M | -$9M | -$5M | -$7M | -$5M | -$6M | -$6M |
| Free cash flow | $142M | $160M | $124M | $97M | $14M | $31M | $60M | $10M |
| Dividends paid | — | — | — | $0 | $0 | $100M | $10M | $25M |
| Buybacks | — | — | — | — | $0 | $0 | $85000 | $808000 |
| Stock-based pay | — | $45M | $31M | $19M | $14M | $6M | $7M | $13M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $276M | $293M | $228M | $132M | $146M | $134M | $82M |
| Debt | — | $23M | $11M | $14M | $15M | $18M | $0 | — |
| Equity | — | $484M | $336M | $34M | $74M | -$73M | $64M | $59M |
| Total assets | — | $939M | $691M | $533M | $403M | $340M | $364M | — |
| Shares (diluted) | 253M | 251M | 251M | 251M | 251M | 251M | 251M | 251M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 84.2% | 84.4% | 83.6% | 81.2% | 82.7% | 80.6% | 79.1% |
| Operating margin | — | 14.0% | 14.2% | 10.2% | 0.4% | 5.6% | 4.7% | -0.9% |
| Net margin | 12.0% | 16.5% | -70.5% | -24.9% | 44.6% | 29.0% | 3.0% | -1.1% |
| FCF margin | 26.4% | 33.7% | 30.8% | 29.8% | 5.1% | 12.6% | 30.9% | 5.8% |
| ROIC | — | 11.3% | 13.0% | 54.3% | 0.9% | — | 7.3% | -2.0% |
| ROE | — | 16.2% | -84.2% | -237.0% | 163.5% | -97.3% | 9.1% | -3.2% |
Frequently asked questions
What is Cellebrite DI’s annual revenue?
$476M in fiscal 2025 and $537M over the twelve months to September 30, 2026.
How much profit does Cellebrite DI make?
Net income was $78M in fiscal 2025 (net margin 16.5%).
Is Cellebrite DI’s revenue growing?
Yes: revenue rose 18.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.